版本:
中国

BRIEF-AstraZeneca receives FDA response to hyperkalaemia drug application

March 17 Astrazeneca Plc

* Receives complete response letter from US FDA for zs-9 (sodium zirconium cyclosilicate) for hyperkalaemia

* Crl does not require generation of any new clinical data

* Astrazeneca and ZS Pharma are committed to working with fda to resolve remaining matters under review as soon as possible Source text for Eikon: Further company coverage: (London newsroom)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐